More tools:Markets·Screener·Research·Chat

BioNexus Gene Lab Corp Common stock (BGLC) Financial Statements

BioNexus Gene Lab Corp Common stock
SIC 8071 · SERVICES-MEDICAL LABORATORIES
FIGI BBG00N70PLZ9
XNAS · usd
1.45▲ 0.05 (3.57%)
As of 2026-09-09
Valuation
Market Cap
Enterprise Value
Trailing P/E—
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close1.40
Day's Range1.35 – 1.43
52-Week Range1.07 – 6.10
Volume3,067
Avg Volume14.8K
Share Statistics
Shares Outstanding
Employees1
ExchangeXNAS
Listed2020-03-11
Share count as of August 14, 2026
Loading Income Statement…
Key questions about BioNexus Gene Lab Corp Common stock (BGLC)
What is BioNexus Gene Lab Corp Common stock's Market Cap?
BioNexus Gene Lab Corp Common stock's Market Cap is $4.3M, based on as-reported figures from SEC (XBRL) filings.
What is BioNexus Gene Lab Corp Common stock's Enterprise Value?
BioNexus Gene Lab Corp Common stock's Enterprise Value is $3.1M, based on as-reported figures from SEC (XBRL) filings.
What is BioNexus Gene Lab Corp Common stock's Price / Sales?
BioNexus Gene Lab Corp Common stock's Price / Sales is 1.4×, based on as-reported figures from SEC (XBRL) filings.
What is BioNexus Gene Lab Corp Common stock's EV / Revenue?
BioNexus Gene Lab Corp Common stock's EV / Revenue is 1.0×, based on as-reported figures from SEC (XBRL) filings.
What is BioNexus Gene Lab Corp Common stock's EV / EBITDA?
BioNexus Gene Lab Corp Common stock's EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is BioNexus Gene Lab Corp Common stock's Revenue (TTM)?
BioNexus Gene Lab Corp Common stock's Revenue (TTM) is $3.1M, based on as-reported figures from SEC (XBRL) filings.
What is BioNexus Gene Lab Corp Common stock's Net Income (TTM)?
BioNexus Gene Lab Corp Common stock's Net Income (TTM) is -$2.6M, based on as-reported figures from SEC (XBRL) filings.
What is BioNexus Gene Lab Corp Common stock's EBITDA?
BioNexus Gene Lab Corp Common stock's EBITDA is -$2.4M, based on as-reported figures from SEC (XBRL) filings.
What is BioNexus Gene Lab Corp Common stock's Diluted EPS (TTM)?
BioNexus Gene Lab Corp Common stock's Diluted EPS (TTM) is -0.88, based on as-reported figures from SEC (XBRL) filings.
What is BioNexus Gene Lab Corp Common stock's EBITDA Margin?
BioNexus Gene Lab Corp Common stock's EBITDA Margin is -78.2%, based on as-reported figures from SEC (XBRL) filings.
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME(LOSS) (Unaudited)
Revenue
YoY growth-96.6%-98.9%-80.8%-3.3%
COST OF REVENUE (Including $nil and $2,307 of cost of revenue from related parties for the three-month period ended June 30, 2026 and 2025, respectively, and $nil and $2,307 of cost of revenue from related parties for the six-month period ended June 30, 2026 and 2025, respectively)
GROSS PROFIT
% of revenue17.0%-3.5%-0.8%14.8%
OTHER INCOME
Interest Income
Non-Operating Income (Expense)
Reversal of expected credit losses
Gain from foreign exchange——
Other Income
TOTAL OTHER INCOME
OPERATING EXPENSES
Sales and marketing
Research and development
General and administrative (Including $nil and $1,012 of rental expenses to related party for the three-month period ended June 30, 2026 and 2025, respectively, and $nil and $2,056 of rental expenses to related party for the six-month period ended June 30, 2026 and 2025, respectively)
Fair value loss on investments in equity securities
Provision for expected credit losses
TOTAL OPERATING EXPENSES
% of revenue-546.8%-2615.3%-217.5%-46.7%
LOSS FROM OPERATIONS
% of revenue-370.8%-2366.2%-213.5%-27.6%
FINANCE COSTS
LOSS BEFORE TAX
Tax expense—
NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS
% of revenue-376.1%-2379.7%-214.2%-27.9%
Earnings Per Share (Diluted)—